Prof. Justin Stebbing

London, UK

Dr. Stebbing is a Professor of Medical Oncology, Imperial College Healthcare NHS Trust (The Hammersmith Hospitals) and NIHR Translational Research Professor, Imperial College, London. Editor-in-Chief, Oncogene. Previously, he is a specialist Registrar in Medical Oncology at Barts and the London NHS Trust and The Royal Marsden NHS Trust; Medical Research Council Clinical Training Fellow, Imperial College London; medical resident The Johns Hopkins Hospital, Baltimore, USA. EDUCATION AND QUALIFICATIONS: 2016 American Society for Clinical Investigation, 2012 NIHR Research Translational Professor (1st national award) 2010 Professor of Cancer Medicine, 2010 FRCP, 2008 FRCPath, 2007 MRCPath, 2003 PhD, 1998 MRCP, 1995 BM BCh MA (Oxon.) AWARDS AND ACHIEVEMENTS: (1) 2020 Global Health Advisor to Greenmantle and several COVID-19 advisory boards including Lilly, with baricitinib being taken into randomised global studies, (2) 2019 Board of Directors for BB Healthcare PLC Trust (stepped down with Chair), (3) 2018 Silver Merit Award continuation, (4) 2016 Editor-in-Chief, Oncogene, Springer Nature’s cancer journal: http://www.nature.com/onc/about.html - present Chair of Boards for BB Healthcare Trust and Xerion Healthcare Fellow of the American Society of Clinical Investigation (www.the-asci.org) Head of clinical/scientific boards: Vor Biopharma, Apobec Ltd and Benevolent AI